These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 18287589)

  • 21. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs.
    Farkouh ME; Greenberg BP
    Am J Cardiol; 2009 May; 103(9):1227-37. PubMed ID: 19406264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Balancing risks and benefits of cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs.
    Scheiman JM
    Gastroenterol Clin North Am; 2009 Jun; 38(2):305-14. PubMed ID: 19446260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The unexpected side effects of new nonsteroidal anti-inflammatory drugs.
    Uzan A
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):687-8. PubMed ID: 16262557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update on nonsteriodal anti-inflammatory drugs.
    Ardoin SP; Sundy JS
    Curr Opin Rheumatol; 2006 May; 18(3):221-6. PubMed ID: 16582683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
    Rostom A; Moayyedi P; Hunt R;
    Aliment Pharmacol Ther; 2009 Mar; 29(5):481-96. PubMed ID: 19053986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclooxygenase-2 inhibitors: what went wrong?
    James MJ; Cleland LG
    Curr Opin Clin Nutr Metab Care; 2006 Mar; 9(2):89-94. PubMed ID: 16477171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs.
    Salpeter SR; Gregor P; Ormiston TM; Whitlock R; Raina P; Thabane L; Topol EJ
    Am J Med; 2006 Jul; 119(7):552-9. PubMed ID: 16828623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs.
    Jones R; Rubin G; Berenbaum F; Scheiman J
    Am J Med; 2008 Jun; 121(6):464-74. PubMed ID: 18501223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction.
    Andersohn F; Suissa S; Garbe E
    Circulation; 2006 Apr; 113(16):1950-7. PubMed ID: 16618816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular risks of cyclooxygenase inhibition.
    Stacy ZA; Dobesh PP; Trujillo TC
    Pharmacotherapy; 2006 Jul; 26(7):919-38. PubMed ID: 16803424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular hazard and non-steroidal anti-inflammatory drugs.
    Wang D; Wang M; Cheng Y; Fitzgerald GA
    Curr Opin Pharmacol; 2005 Apr; 5(2):204-10. PubMed ID: 15780832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor.
    Warner JJ; Weideman RA; Kelly KC; Brilakis ES; Banerjee S; Cunningham F; Harford WV; Kazi S; Little BB; Cryer B
    J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):252-60. PubMed ID: 18787084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
    Dajani EZ; Islam K
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis.
    Becker MC; Wang TH; Wisniewski L; Wolski K; Libby P; Lüscher TF; Borer JS; Mascette AM; Husni ME; Solomon DH; Graham DY; Yeomans ND; Krum H; Ruschitzka F; Lincoff AM; Nissen SE;
    Am Heart J; 2009 Apr; 157(4):606-12. PubMed ID: 19332185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonsteroidal anti-inflammatory drugs: are they safe after joint arthroplasty for early pain?
    Purtill JJ
    Instr Course Lect; 2007; 56():133-7. PubMed ID: 17472301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals.
    Fosbøl EL; Køber L; Torp-Pedersen C; Gislason GH
    Expert Opin Drug Saf; 2010 Nov; 9(6):893-903. PubMed ID: 20569079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis.
    Singh G; Wu O; Langhorne P; Madhok R
    Arthritis Res Ther; 2006; 8(5):R153. PubMed ID: 16995929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
    Farkouh ME; Greenberg JD; Jeger RV; Ramanathan K; Verheugt FW; Chesebro JH; Kirshner H; Hochman JS; Lay CL; Ruland S; Mellein B; Matchaba PT; Fuster V; Abramson SB
    Ann Rheum Dis; 2007 Jun; 66(6):764-70. PubMed ID: 17412741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs in high doses increases mortality and risk of reinfarction in patients with prior myocardial infarction.
    Sørensen R; Abildstrom SZ; Torp-Pedersen C; Gislason GH
    J Cardiovasc Nurs; 2008; 23(1):14-9. PubMed ID: 18158501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk.
    Woodruff T
    Intern Med J; 2006 Dec; 36(12):797-8; author reply 798-9. PubMed ID: 17096747
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.